Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD

BACKGROUND: Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor, has been shown to improve survival in non-small cell lung cancer (NSCLC). The possible involvement of PD-1 axis in the pathogenesis of inflammatory lung disease, such as chronic obstructive pulmonary disease (COPD) has a...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Yuzo, Inui, Naoki, Karayama, Masato, Imokawa, Shiro, Yamada, Takashi, Yokomura, Koushi, Asada, Kazuhiro, Kusagaya, Hideki, Kaida, Yusuke, Matsuda, Hiroyuki, Koshimizu, Naoki, Toyoshima, Mikio, Masuda, Masafumi, Hayakawa, Hiroshi, Hozumi, Hironao, Furuhashi, Kazuki, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Nakamura, Yutaro, Suda, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709515/
https://www.ncbi.nlm.nih.gov/pubmed/31686799
http://dx.doi.org/10.2147/COPD.S214610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709515/
https://www.ncbi.nlm.nih.gov/pubmed/31686799
http://dx.doi.org/10.2147/COPD.S214610

Ejemplares similares